BRCA1 and ovarian carcinoma: In addition, upcoming trials of PARP inhibitors in ovarian cancer that specifically enrich for BRCA1 and BRCA2 carriers may be at particular risk for confounding biases in treatment response if differences in between these two biologically distinct groups are not considered.